The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

Vasilios G. Athyros(Neurosciences Institute), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Απόστολος Τσάπας(Aristotle University of Thessaloniki), Όλγα Γιουλεμέ(Hippocration General Hospital), Theodore K. Alexandrides(University of Patras), Charalambos Vlachopoulos(National and Kapodistrian University of Athens), Lοukianos S. Rallidis(National and Kapodistrian University of Athens), Alexandros D. Tselepis(University of Ioannina), Christos Pitsavos(National and Kapodistrian University of Athens), Jannis Kountouras(Aristotle University of Thessaloniki), Dimitrios Richter(Athens Euroclinic), Moses Elisaf(University of Ioannina), Niki Katsiki(Neurosciences Institute), Konstantinos Tsioufis(National and Kapodistrian University of Athens), Charalambos Karvounis(AHEPA University Hospital), Εvangelos Cholongitas, Asterios Karagiannis(Hippocration General Hospital), Κωνσταντίνος Τζιόμαλος(AHEPA University Hospital), Michael Doumas(Hippocration General Hospital), John Goudevenos(University Hospital of Ioannina), Evangelos Liberopoulos(National and Kapodistrian University of Athens), Georgios Germanidis(Aristotle University of Thessaloniki), Dimitri P. Mikhailidis(Neurosciences Institute), Themistoklis Tzotzas(St. Luke's Hospital), Themistoklis G. Vasiliadis(Papageorgiou General Hospital), Vasilios Kotsis(Aristotle University of Thessaloniki), Helen Bilianou(Tzaneion General Hospital), Emmanuel S. Ganotakis(University of Crete)
Metabolism
March 5, 2017
Cited by 251


Related Papers